Clinical trials: IDIOPATHIC PARKINSON'S DISEASE
- Condition IDIOPATHIC PARKINSON'S DISEASE
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Parkinson Disease
Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as shown below through the Post Marketing Surveillance (PMS) study upon approval.
- Trial name
- NCT02248168
- Testing
- Pramipexole
- Volunteers
- 1,449 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
Documentation of the effect of SIFROL® on tremor and depression as well as its tolerability in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions
- Trial name
- NCT02231294
- Testing
- Sifrol®
- Volunteers
- 1,464 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Parkinson's Disease
Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
The primary objective of this study is to evaluate the perception of pain associated with Parkinson´s Disease in patients who receive Neupro® for the first time.
- Trial name
- NEUPAD (NCT01606670)
- Where
- 27 sites in Austria, Germany
- Volunteers
- 93 people
- Sponsor
- UCB Pharma GmbH
Parkinson Disease
Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor, depression, anhedonia and tolerability
- Trial name
- NCT02248220
- Testing
- Pramipexole
- Volunteers
- 657 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease
Study to document pramipexole dosing during monotherapy, occurrence of fluctuations and dyskinesias, dose increases after deterioration of Parkinson's disease (PD) symptoms, assessment of the reasons for add-on treatment with…
- Trial name
- NCT02248181
- Testing
- Pramipexole
- Volunteers
- 442 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for…
- Trial name
- NCT02231255
- Testing
- Sifrol®
- Volunteers
- 1,216 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Parkinson's Disease
Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
The study intends to collect data on gastrointestinal symptoms (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, diarrhea) and on patient satisfaction under everyday practice conditions…
- Trial name
- NON-GI (NCT01159691)
- Where
- 21 sites in Germany
- Volunteers
- 76 people
- Sponsor
- UCB Pharma GmbH
Parkinson's Disease
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study .
- Trial name
- NCT01856439
- Testing
- ProSavin
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Axovant Sciences Ltd.
Idiopathic Parkinson Disease
Transdermal Rotigotine User Surveillance Study
This study will be conducted in an observational multiple-cohort design aimed at acquiring clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD) will be enrolled.
- Trial name
- TRUST (NCT00599339)
- Where
- 211 sites in Czechia, Denmark and 8 more
- Volunteers
- 2,195 people
- Sponsor
- UCB Pharma